Literature DB >> 23125243

A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.

Ellen Weisberg, Martin Sattler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23125243      PMCID： PMC3487432          DOI： 10.3324/haematol.2012.078451

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Authors:  Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

2.  Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy.

Authors:  Noriaki Mitani; Yoshimasa Niwa; Yasuyuki Okamoto
Journal:  Ann Clin Biochem       Date:  2007-11       Impact factor: 2.057

3.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Authors:  Cheuk Him Man; Tsz Kan Fung; Christa Ho; Heron H C Han; Howard C H Chow; Alvin C H Ma; William W L Choi; Si Lok; Alice M S Cheung; Connie Eaves; Yok Lam Kwong; Anskar Y H Leung
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

4.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

6.  P53 mutations and other prognostic factors of renal cell carcinoma.

Authors:  C Girgin; H Tarhan; M Hekimgil; A Sezer; G Gürel
Journal:  Urol Int       Date:  2001       Impact factor: 2.089

7.  The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Authors:  Giorgio Zauli; Claudio Celeghini; Elisabetta Melloni; Rebecca Voltan; Manuele Ongari; Mario Tiribelli; Maria Grazia di Iasio; Francesco Lanza; Paola Secchiero
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

8.  Sporadic p53 mutations and absence of ras mutations in glioblastomas.

Authors:  E Gömöri; T Dóczi; L Pajor; A Matolcsy
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

9.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Authors:  Weiguo Zhang; Marina Konopleva; Yue-xi Shi; Teresa McQueen; David Harris; Xiaoyang Ling; Zeev Estrov; Alfonso Quintás-Cardama; Donald Small; Jorge Cortes; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

10.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Authors:  A B Williams; B Nguyen; L Li; P Brown; M Levis; D Leahy; D Small
Journal:  Leukemia       Date:  2012-07-13       Impact factor: 11.528
View more
  2 in total

Review 1.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014

Review 2.  Motif mediated protein-protein interactions as drug targets.

Authors:  Carles Corbi-Verge; Philip M Kim
Journal:  Cell Commun Signal       Date:  2016-03-02       Impact factor: 5.712
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.